Zhang Yong-Zhen, Ma Jun-Fei, Zhao Fang-Hui, Xiang Xi-E, Ma Zhao-Hui, Shi Ying-Tao, Hu Shang-Ying, Qiao You-Lin
Department of Epidemiology, Shanxi Province Cancer Institute, Taiyuan, Shanxi 030013, People's Republic of China.
Chin J Cancer. 2010 Jan;29(1):4-8. doi: 10.5732/cjc.009.10687.
In China, there has been no established national program for cervical cancer prevention, the screening methods and experiences are especially deficient in the rural areas. The aim of this paper is to evaluate the effects of acetic acid/Lugol's iodine (VIA/VILI) used for screening of cervical cancer and pre-cancerous lesions in a rural area of China by analyzing the large-scale population-based screening data from the demonstration site.
Women aged 30-59 years from Xiangyuan County in Shanxi Province were recruited for cervical cancer screening from 2005 to 2007. VIA/VILI was the primary screening method followed by colposcopy if the VIA/VILI was positive. Cervical lesions were diagnosed by directed biopsy under the colposcopy. The VIA/VILI negative women or cervical intraepithelial neoplasia 1 (CIN1) were re-screened using the same procedure in the next year.
In total, 7145 women received the cervical cancer screening, with a participation rate of 74.75%. Their average age was 42.16 years. A total of 1287 women were consecutively screened for three times from 2005 to 2007. The detection rates of CIN2, CIN3 and cervical cancer were 0.70% (9/1287), 1.01% (13/1287) and 0.23% (3/1287) for the first round screening, and were 0.22% (2/976), 0.11% (1/976) and 0% (0/976) for the second round screening, respectively. Only one CIN2 was found in the third round screening. In the years of 2006-2007, 3490 women were screened consecutively twice. The detection rates of CIN2, CIN3 and cervical cancer were 0.26% (9/3490), 0.52% (18/3490) and 0.15% (5/3490) for the first round screening, and 0.40% (14/2943), 0.40% (14/2943) and 0.03% (1/2943) for the second round screening. Likewise, 2 368 women were screened consecutively twice in the years of 2007-2008. The detection rates of CIN2, CIN3 and cervical cancer were 0.55% (13/2368), 0.25% (6/2368) and 0.12% (3/2368) for the first round screening, and 0.42 (10/2040), 0.04% (1/2040) and 0% for the second round screening. The cumulative detection rates for CIN2, CIN3 and cervical cancer were 0.81% (58/7145), 0.74% (53/7145) and 0.17% (12/7145), respectively. And 53.45% (31/58) of CIN2, 68.81% (37/53) of CIN3 and almost all cervical cancers (11/12) were found during the first round screening, except for an early stage cervical cancer (Ia). Only one CIN2 was detected in the third round screening in the same population. The average age of CIN1, CIN2, CIN3 and cervical cancer were 38.65, 40.61, 44.10 and 46.73 years, respectively.
VIA/VILI can be used as an alternative screening method for cervical cancer and high-grade pre-cancerous lesions among the women aged 30-59 years in China's rural areas because of its low cost, easy training for the local health providers, and less depending on facilities. One round screening by VIA/VILI can detect more than a half of CIN2, two-thirds of CIN3 and almost all the cervical cancer in the population, and the detection rates of CIN2/3 can be increased by two consecutive rounds of screening.
在中国,尚未建立全国性的宫颈癌预防项目,农村地区的筛查方法和经验尤为匮乏。本文旨在通过分析来自示范地区基于大规模人群的筛查数据,评估醋酸/卢戈氏碘染色法(VIA/VILI)用于中国农村地区宫颈癌及癌前病变筛查的效果。
2005年至2007年,招募山西省襄垣县30 - 59岁的女性进行宫颈癌筛查。VIA/VILI为主要筛查方法,若VIA/VILI结果为阳性,则进一步行阴道镜检查。通过阴道镜下直接活检诊断宫颈病变。VIA/VILI结果为阴性的女性或宫颈上皮内瘤变1级(CIN1)的女性于次年采用相同程序再次筛查。
共有7145名女性接受了宫颈癌筛查,参与率为74.75%。她们的平均年龄为42.16岁。2005年至2007年共有1287名女性连续接受了三次筛查。第一轮筛查中,CIN2、CIN3和宫颈癌的检出率分别为0.70%(9/1287)、1.01%(13/1287)和0.23%(3/1287),第二轮筛查中分别为0.22%(2/976)、0.11%(1/976)和0%(0/976)。第三轮筛查仅发现1例CIN2。2006年至2007年,3490名女性连续接受了两次筛查。第一轮筛查中,CIN2、CIN3和宫颈癌的检出率分别为0.26%(9/3490)、0.52%(18/3490)和0.15%(5/3490),第二轮筛查中分别为0.40%(14/2943)、0.40%(14/2943)和0.03%(1/2943)。同样,2007年至2008年,2368名女性连续接受了两次筛查。第一轮筛查中,CIN2、CIN3和宫颈癌的检出率分别为0.55%(13/2368)、0.25%(6/2368)和0.12%(3/2368),第二轮筛查中分别为0.42(10/2040)、0.04%(1/2040)和0%。CIN2、CIN3和宫颈癌的累积检出率分别为0.81%(58/7145)、0.74%(53/7145)和0.17%(12/7145)。除1例早期宫颈癌(Ia期)外,53.45%(31/58)的CIN2、68.81%(37/53)的CIN3以及几乎所有宫颈癌(11/12)均在第一轮筛查中被发现。同一人群的第三轮筛查仅检测到1例CIN2。CIN1、CIN2、CIN3和宫颈癌患者的平均年龄分别为38.65岁、40.61岁、44.10岁和46.73岁。
VIA/VILI因其成本低、便于对当地卫生人员进行培训且对设备依赖少,可作为中国农村地区30 - 59岁女性宫颈癌及高级别癌前病变的替代筛查方法。VIA/VILI一轮筛查可检测出人群中超过一半的CIN2、三分之二的CIN3以及几乎所有宫颈癌,连续两轮筛查可提高CIN2/3的检出率。